

Statewide Standard Treatment Protocol

Peace Officer Naloxone (Narcan®) Standing Order



Effective: November 1, 2022

Approved by the EMS Medical Directors: April 13, 2022

Approved by the Advanced Life Support Subcommittee of the Board of Medical License and Discipline: May 18, 2022

Approved by the Board of Medical Licensure and Discipline: June 7, 2022

Rick Hong, MD
Emergency Medical Services & Preparedness Section Medical Director
Division of Public Health

Robert A. Rosenbaum, MD., FACEP, FAEMS
State EMS Medical Director
Office of Emergency Medical Services

Public Safety Personnel Naloxone (Narcan) Standing Order

Available to Peace Officer Agencies that Select to Participate on Written Approval of the State EMS Director and State EMS Medical Director

INDICATIONS: Respiratory distress as evidenced with slow respirations or no breathing (apnea). This protocol will allow Peace Officers to treat patients with a history based on bystanders, provider's prior knowledge of the patient, or suspicion of potential narcotic overdose as evidenced by nearby medications or drug paraphernalia.

- Perform scene survey.
 - Scene Safety
 - Observe body substance isolation (BSI) precautions. (Follow your agency's infection control policy and Infection Control Protocol)
 - Observe patient position and surroundings that have contributed to the injury.
 - Check for level of consciousness
 - Initiate or verify that there is an EMS response
 - Begin CPR if appropriate
 - Be alert to signs of trauma on physical exam.
 - Manage cervical spine as needed.
 - Administer 2 mg to 4 mg Naloxone (Narcan®) to provide for a patient, self-maintained airway and adequate respirations.
 - If no improvement in the patient's respiratory status after four (4) minutes, an additional 2 mg may be given. **Maximum dose of 4 mg on this protocol.**
 - **Caution:** patients with near complete reversal of a narcotic overdose **may become very agitated and combative.**
 - Continue to manage the patient's airway until they are breathing adequately and are able to protect their airway from aspirating vomitus.
 - Do not delay safe transport to await results of treatment.
 - Give a verbal report to responding Emergency Medical Service providers.
-

Medication and Administration Device:

NALOXONE (NARCAN®)

Description: Naloxone is an opioid antagonist.

Pharmacology: Naloxone is a competitive narcotic antagonist, which reverses all effects of opioids (i.e. morphine), such as respiratory depression and central and peripheral nervous system effects.

Indications: Naloxone is indicated to reverse respiratory and central nervous system depression induced by opioids.

Onset/Duration: The onset of action is within a few minutes following an intravenous dose, whereas intramuscular and endotracheal/intranasal administration results in a slower onset of action. The duration of action is approximately 30-60 minutes.

Dosage and Routes of Administration: Administer a dose of at least 2 mg and up to 4 mg intra-nasally of naloxone (Narcan®) to provide for a patent, self-maintained airway and adequate respirations. (A 4 mg dose may be given as a single 4 mg spray in one nostril or two 2 mg intranasal doses).

2 mg intranasal naloxone consists of a syringe with an atomizer which is assembled and administered in two (2) half doses in each nostril.

4 mg intranasal naloxone (Narcan®) is a nasal spray administered in a single dose in one (1) nostril.

Maximum dose of 4 mg on this protocol.

Storage: Store at 20-25°C (68-77°). Protect from light.